ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Worst Performer on NASDAQ

<< Previous

Bullboard Posts

Next >>

Post by goldtechon Nov 10, 2023 11:20am

200 Views

Post# 35728466

Worst Performer on NASDAQ

These people could not run a one hole outhouse and Gail now wins the award of being the CEO that has seen our shares go to all time lows. Great job Gail and Gene and we pay you how much for your incompetence?

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"